
Grifols, S.A. GRFS
€ 6.52
-1.38%
Geschäftsbericht 2024
hinzugefügt 14.03.2026
Land |
|
IPO-Jahr |
- |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ GLOBAL |
Anteile |
- |
Marktkapitalisierung |
$ 6.83 B |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Ultragenyx Pharmaceutical
RARE
|
$ 19.23 | -3.85 % | $ 1.9 B | Nasdaq Global Select Market,SPB | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
RedHill Biopharma Ltd.
RDHL
|
$ 0.8 | 0.89 % | $ 428 M | Nasdaq Global Market | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 13.56 | -1.56 % | $ 2.25 B | NYSE | ||
|
Regeneron Pharmaceuticals
REGN
|
$ 742.02 | -1.94 % | $ 77.6 B | Nasdaq Global Select Market,SPB | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Replimune Group
REPL
|
$ 7.22 | -4.24 % | $ 582 M | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
REGENXBIO
RGNX
|
$ 7.88 | -4.6 % | $ 406 M | Nasdaq Global Select Market,SPB | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Rigel Pharmaceuticals
RIGL
|
$ 26.2 | -0.64 % | $ 471 M | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Avidity Biosciences
RNA
|
$ 13.09 | -0.08 % | $ 1.8 B | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 78.52 | -4.13 % | $ 5.1 B | Nasdaq Global Market,SPB | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 12.57 | -9.96 % | $ 1.91 B | Nasdaq Global Select Market,SPB | ||
|
Sana Biotechnology
SANA
|
$ 2.78 | -8.42 % | $ 704 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
SIGA Technologies
SIGA
|
$ 5.35 | 7.76 % | $ 383 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 321.71 | -1.96 % | $ 42.1 B | Nasdaq Global Select Market,SPB | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | ||
|
Silence Therapeutics plc
SLN
|
$ 4.8 | -9.6 % | $ 622 M | Nasdaq Global Select Market | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.08 | -0.92 % | $ 22.2 M | Nasdaq Capital Market | ||
|
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market |